Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

被引：0

作者：

Fox, Christopher P. ^{[1
]}

Townsend, William ^{[2
]}

Gribben, John G. ^{[3
]}

Menne, Tobias ^{[4
]}

Kalakonda, Nagesh ^{[5
]}

Williams, Paula ^{[6
]}

Toron, Farah ^{[6
]}

Tyas, Emma ^{[7
]}

Cooper, Miranda ^{[7
]}

Rickards, Joshua ^{[7
]}

Radford, John ^{[8
,9
]}

机构：

[1] Univ Nottingham, Sch Med, Nottingham, England

[2] Univ Coll London Hosp, NHS Fdn Trust, London, England

[3] Barts Hlth NHS Trust, Barts Canc Inst, London, England

[4] Newcastle Tyne Hosp, NHS Fdn Trust, Newcastle Upon Tyne, England

[5] Univ Liverpool, Mol & Clin Canc Med, Liverpool, England

[6] Bristol Myers Squibb, Uxbridge, England

[7] Lumanity, Farnham, England

[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England

[9] Univ Manchester, Manchester, England

来源：

EJHAEM | 2024年 / 5卷 / 05期

关键词：

ASCT; LBCL; outcomes; real-world evidence; TRANSPLANTATION;

D O I：

10.1002/jha2.970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

引用

页码：992 / 997

页数：6

共 50 条

[31] Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, Michael J.
Carlo-Stella, Carmelo
Morschhauser, Franck
Bachy, Emmanuel
Corradini, Paolo
Iacoboni, Gloria
Khan, Cyrus
Wrobel, Tomasz
Offner, Fritz
Wu, Shang-Ju
Cartron, Guillaume
Hertzberg, Mark
Sureda, Anna
Perez-Callejo, David
Lundberg, Linda
Relf, James
Dixon, Mark
Clark, Emma
Humphrey, Kathryn
Hutchings, Martin
Trney, Marek
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (24) : 2220 - 2231
[32] How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
Wallace, Danielle S.
Loh, Kah Poh
Casulo, Carla
BLOOD, 2025, 145 (03) : 277 - 289
[33] Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma
Esteghamat, Naseem
Tsumura, Aaron
Marquez-Arreguin, Gabriel
Tuscano, Joseph
FRONTIERS IN ONCOLOGY, 2024, 14
[34] Incidence of second primary malignancies in relapsed/refractory B-cell non-Hodgkin's lymphoma patients in England
Miret, Montserrat
Anderson, Amanda
Hindocha, Pooja
Cirneanu, Lorena
Lymperopoulou, Christina
Markov, Emanuil
Kizito, William
Vegni, Ferdinando Emanuele
LEUKEMIA RESEARCH, 2023, 127
[35] Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure
Hu, Junxia
Wang, Xin
Chen, Fei
Ding, Mengjie
Dong, Meng
Yang, Wanqiu
Yin, Meifeng
Wu, Jingjing
Zhang, Lei
Fu, Xiaorui
Sun, Zhenchang
Li, Ling
Wang, Xinhua
Li, Xin
Guo, Shuangshuang
Zhang, Dianbao
Lu, Xiaohui
Leng, Qing
Zhang, Mingzhi
Zhu, Linan
Zhang, Xudong
Chen, Qingjiang
FRONTIERS IN ONCOLOGY, 2021, 11
[36] Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era
Xie, Jipan
Wu, Aozhou
Liao, Laura
Nastoupil, Loretta J.
Du, Ella Xiaoyan
Noman, Ahmed
Chen, Lei
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (10) : 1789 - 1798
[37] Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T- Cell Therapy in the US
Epperla, Narendranath
Lucero, Melanie
Bailey, Tom
Mirams, Laura
Cheung, Jolenta
Amet, Mona
Milligan, Gary
Keir, Chris
Chen, Lei
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S476 - S476
[38] Economic burden in treated Japanese patients with relapsed/refractory large B-cell lymphoma
Tsutsue, Saaya
Makita, Shinichi
Yi, Jingbo
Crawford, Bruce
FUTURE ONCOLOGY, 2021, 17 (33) : 4511 - 4525
[39] Real-World Survival, Healthcare Resource Utilization, and Costs Among US Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting
Garg, Mahek
Puckett, Justin
Kamal-Bahl, Sachin
Raut, Monika
Ryland, Katherine Elizabeth
Doshi, Jalpa A.
Huntington, Scott F.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (05) : e181 - e190
[40] Relapsed or Refractory Diffuse Large B-Cell Lymphoma: "Dazed and Confused"
Kesireddy, Meghana
Lunning, Matthew A.
ONCOLOGY-NEW YORK, 2022, 36 (06): : 360 - 369

← 1 2 3 4 5 →